May 2015

Dy: For RET - fusion in 1-2% in LUAD, mutations 1-2% SCLC. PII trials in RET+ NSCLC #ASCO15

3:28pm May 29th 2015 via Hootsuite

Dy: PI clinical trials for FGFR1-3 inhibitors in FGFR1-amplifiied LUSC. Adverse event of hyperphosphatemia #ASCO15

3:26pm May 29th 2015 via Hootsuite

Dy: FGFR has both amplification and mutations in extra-cellular domain; also have fusion products (TACC3 3% in LUSC) #ASCO15

3:24pm May 29th 2015 via Hootsuite

Grace Dy (Roswell Park) "Clinical Trials and Treatment for Mutations Other Than EGFR/ALK/ROS1" #ASCO15

3:21pm May 29th 2015 via Hootsuite

ALCHEMIST reference: Gerber '15 http://t.co/NmUPrgUN3C #ASCO15

3:18pm May 29th 2015 via Hootsuite

Mok: ALCHEMIST EGFR treatment as well (erlotinib vs placebo). Another endpoint: recurrence will be characterized. #ASCO15

3:16pm May 29th 2015 via Hootsuite

Mok: ALCHEMIST trial (NCTN): ALK+ pts, 2y of crizotinib vs placebo; use OS as primary endpoint. Challenge: pt recruitment #ASCO15

3:16pm May 29th 2015 via Hootsuite

Mok: Concl: No evidence of improvement of overall survival. We need to know: 2 studies have insufficient #'s for overall survival #ASCO15

3:14pm May 29th 2015 via Hootsuite

Mok: Duration of erlotinib also impact results (due to toxicity). GIST showed no overall survival improvement in '09. #ASCO15

3:11pm May 29th 2015 via Hootsuite

Mok: Overall survival didn't change; CNS recurrance common in pts w/ adjuvant TKI. 'may have delayed systemic recurrence' #ASCO15

3:09pm May 29th 2015 via Hootsuite

Mok: Reviewed several smaller studies where few conclusions can be made. RADIANT reported by Shepherd ASCO14 - 70% 5y survival. #ASCO15

3:08pm May 29th 2015 via Hootsuite

Mok: The outcome is higher chance of 5y survival - what is baseline w/o adjuvant TKI? Limited: Kosaka '09 http://t.co/LORzUOkHvc #ASCO15

3:01pm May 29th 2015 via Hootsuite

Tony Mok (Chinese Univ HK) "Molecularly Targeted Therapies: Their Trials and Roles in the Adjuvant and Postchemoradiation Setting" #ASCO15

2:58pm May 29th 2015 via Hootsuite

Ladanyi: NGS feasible, streamlined lab workflow, opt pt stratification. 'Rapid gen. of big datasets will drive further discoveries' #ASCO15

2:57pm May 29th 2015 via Hootsuite

Ladanyi: Used Nanostring to look at MET exon 14 expression; just published Paik '15 ref http://t.co/zXFW5CHx37 #ASCO15

2:56pm May 29th 2015 via Hootsuite

Ladanyi: Met oncogene w/skipping exon 14. TCGA July '14 Nature: 4% of cases. Exon 14 encodes a ubiquitin target, turnover reduced #ASCO15

2:54pm May 29th 2015 via Hootsuite

Ladanyi: Fusion frequency chart - ranging from 4.8% and below #ASCO15

2:52pm May 29th 2015 via Hootsuite

Ladanyi: CD74/ROS1 fusion illust.; complex example of ROS1 6q22 re-arrangement. Crizotinib showed pt response #ASCO15

2:51pm May 29th 2015 via Hootsuite

Ladanyi:Gene fusions can be picked up via hyb capture method - some will span breakpoint. Has 14 ca fusion genes (ALK, RET, ROS) ASCO15

2:50pm May 29th 2015 via Hootsuite

Ladanyi: Can det gene copy number - showed bar chart of 10 most common CNV (EGFR, NIKK2). Del: P15, PTEN, RB1 #ASCO15

2:49pm May 29th 2015 via Hootsuite

Ladanyi:Showed list of most common mutations (TP53, EGFR etc.) and distribution of them ASCO15

2:48pm May 29th 2015 via Hootsuite

Ladanyi:Failure rate - 11% for cytology samples, lower for others. Showed example of EGFR mutation cp to matched normal ASCO15

2:48pm May 29th 2015 via Hootsuite

Ladanyi: Run 125 cases/wk; started in Jan '14. 6K cases/yr. Open to all solid cancers. Most common: br, colorectal, lung #ASCO15

2:46pm May 29th 2015 via Hootsuite

Ladanyi:Matched normal blood; need >20% tumor. 341 genes; 33 introns of 14 rearr genes. Lower limit: 2% for hotspot; 5% for non. #ASCO15

2:45pm May 29th 2015 via Hootsuite

Ladanyi: Recent publication http://t.co/8bm1aH0Wja has gene list of MSK-IMPACT and their results to-date. 3w turnaround time #ASCO15

2:43pm May 29th 2015 via Hootsuite

Ladanyi: Use exon capture (either hyb or PCR-based). MSK-IMPACT uses hyb capture of 410 genes, NimbleGen, then HiSeq #ASCO15

2:42pm May 29th 2015 via Hootsuite

Ladanyi:Multiplex panel testing for NGS - small biopsy specimens; NGS more efficient, lower cost cited. #ASCO15

2:41pm May 29th 2015 via Hootsuite

Ladanyi: SQNM panel '09-'13: 91 mutations in 8 genes. MAP2K1 (MEK1) mutations #ASCO15 '14 Arcila ref http://t.co/dB0z1OMBch

2:40pm May 29th 2015 via Hootsuite

Ladanyi: Lung adenocarcinoma: 29K KRAS; 20K EGFR; long tail (BRAF 1500, ERBB2 2K etc) ~40% no known driver #ASCO15

2:38pm May 29th 2015 via Hootsuite

Ladanyi: At MSKCC - started in '04 with EGFR; '06 +KRAS; '09 to SQNM; '13 +ALK FISH, +ISH '14 NGS #ASCO15

2:37pm May 29th 2015 via Hootsuite

Marc Ladanyi (MSKCC) "Next-Generation Sequencing and Other Platforms for Molecular Profiling" #ASCO15

2:36pm May 29th 2015 via Hootsuite

Edelman: 2nd, 3d line treatment depends on prior treatment. #ASCO15

2:35pm May 29th 2015 via Hootsuite

Edelman: Role and order of agents is evolving; plat-based two-drug therapy w/wo bevacizumab, w/wo maint is std first-line apprch #ASCO15

2:35pm May 29th 2015 via Hootsuite

Edelman: SWOG 1400 - variety of targeted agents, four different arms. #ASCO15

2:34pm May 29th 2015 via Hootsuite

Edelman: Future questions - role of immunotherapy in 1st line? Replace, maint., biomarker, combinations? #ASCO15

2:33pm May 29th 2015 via Hootsuite

Edelman: EGFR TKI's for SCC: in '99 thought most likely to have activity. Erlotinib licensed in 2nd and 3rd line regardless of hist #ASCO15

2:32pm May 29th 2015 via Hootsuite

Edelman: Anti-PD1 and anti-PD-L1 - results presented at #ASCO15.. What is the optimal second-line therapy? Nivo vs. docetaxel?

2:30pm May 29th 2015 via Hootsuite

Edelman: Second line therapy - Doc v Pem gave similar results, Erlotinib v Placebo. A year ago: "Life has changed" #ASCO15

2:28pm May 29th 2015 via Hootsuite

Edelman: Histology and anti-VEGF; ECOG 4599 became std for NSCLC; add'l 2 trials differentiate betw. squamous & non-squamous #ASCO15

2:21pm May 29th 2015 via Hootsuite

Edelman: Lung ca 'used to be simple'; 85-95% don't have actionable mut's. First-line: histology's importance #ASCO15

2:19pm May 29th 2015 via Hootsuite

Martin J. Edelman Systemic Therapy of Pan-WT in Metastatic Setting #ASCO15

2:18pm May 29th 2015 via Hootsuite

RT @ChrisPascale6: Hey #ASCO15 peeps- you should head over to the '"Unofficial" ASCO '15 Tweetup" tonite! dooo itt! http://t.co/Ndx03YatQU …

1:30pm May 29th 2015 via Mobile Web (M5)

RT @DrMiguelPerales: #ASCO15: Abstract Thoughts On Cancer And Competition http://t.co/Fc285Om8Pf via @forbes http://t.co/BCbYl45TV6

11:15am May 29th 2015 via Hootsuite

RT @theNCI: What's NCI's National Clinical Trials Network? Our new overview explains: http://t.co/ut8gK8qsEW #ASCO15 http://t.co/2XW80ZScKN

10:48am May 29th 2015 via Hootsuite

RT @SteveStuWill: Blue-collar men in rich countries are in trouble. http://t.co/sYYIfM9BIw "Men cluster at the bottom as well as the top."

10:33am May 29th 2015 via Hootsuite

RT @edyong209: Spot-on analysis of the ethical flaws and spurious claims of that chocolate hoax https://t.co/q1E4JCqs9g By @rehrenberg

7:05am May 29th 2015 via Hootsuite

The way Uber fares are calculated is a mess | Fusion http://t.co/LdVZJdFPUK

10:20pm May 28th 2015 via Hootsuite

Scenes From Underground - The Atlantic http://t.co/WuBFhj6lo3

9:30pm May 28th 2015 via Hootsuite